DE69232968T2 - CDR ausgetauschte humanisierte chimäre T-Zellenantikörper. - Google Patents

CDR ausgetauschte humanisierte chimäre T-Zellenantikörper.

Info

Publication number
DE69232968T2
DE69232968T2 DE69232968T DE69232968T DE69232968T2 DE 69232968 T2 DE69232968 T2 DE 69232968T2 DE 69232968 T DE69232968 T DE 69232968T DE 69232968 T DE69232968 T DE 69232968T DE 69232968 T2 DE69232968 T2 DE 69232968T2
Authority
DE
Germany
Prior art keywords
cdr
pct
exchanged
cell antibodies
humanized chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232968T
Other languages
English (en)
Other versions
DE69232968D1 (de
Inventor
Herman Waldmann
Louise Walsh
Scott Crowe
Peter Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge University Technical Services Ltd CUTS filed Critical Cambridge University Technical Services Ltd CUTS
Publication of DE69232968D1 publication Critical patent/DE69232968D1/de
Application granted granted Critical
Publication of DE69232968T2 publication Critical patent/DE69232968T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
DE69232968T 1991-12-06 1992-12-04 CDR ausgetauschte humanisierte chimäre T-Zellenantikörper. Expired - Fee Related DE69232968T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919125979A GB9125979D0 (en) 1991-12-06 1991-12-06 Antibody
PCT/GB1992/002251 WO1993011237A1 (en) 1991-12-06 1992-12-04 Cdr grafted humanised chimeric t-cell antibodies

Publications (2)

Publication Number Publication Date
DE69232968D1 DE69232968D1 (de) 2003-04-24
DE69232968T2 true DE69232968T2 (de) 2003-11-06

Family

ID=10705825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232968T Expired - Fee Related DE69232968T2 (de) 1991-12-06 1992-12-04 CDR ausgetauschte humanisierte chimäre T-Zellenantikörper.

Country Status (9)

Country Link
US (1) US5502167A (de)
EP (1) EP0667902B1 (de)
JP (1) JP3339637B2 (de)
AT (1) ATE234923T1 (de)
DE (1) DE69232968T2 (de)
DK (1) DK0667902T3 (de)
ES (1) ES2194011T3 (de)
GB (1) GB9125979D0 (de)
WO (1) WO1993011237A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) * 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
JP4423680B2 (ja) 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
PT959899E (pt) * 1996-08-16 2009-08-28 Univ Catholique Louvain Anticorpo lo-cd2a e suas utilizações para inibir a activação e proliferação de células t
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
PT966533E (pt) 1997-02-07 2010-01-26 Univ Ramot Factor neurotrófico iii dependente da actividade (adnf iii)
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
JP4044733B2 (ja) 1998-05-20 2008-02-06 帝人株式会社 ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
WO2000002584A2 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
DK2283868T3 (en) 2002-07-15 2016-04-25 Univ Texas PEPTIDES BINDING TO PHOSPHATIDYLETHANOLAMINE AND ITS USE IN TREATING VIRUS INFECTIONS AND CANCER
AU2003304411A1 (en) 2002-08-01 2005-03-07 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1629090B1 (de) * 2002-11-06 2014-03-05 iBio, Inc. Expression von fremdsequenzen in pflanzen unter verwendung eines trans-aktivierungssystems
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP4741242B2 (ja) 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1594956A4 (de) 2003-02-03 2007-08-01 Fraunhofer Usa Inc System zur expression von genen in pflanzen
CA2520121A1 (en) * 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
CN1922306B (zh) * 2004-02-20 2010-10-06 美国弗劳恩霍夫股份有限公司 用于植物中克隆表达的系统和方法
CA2560508A1 (en) * 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EP2153848A3 (de) 2005-01-27 2010-07-21 The Regents of the University of California Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
BRPI0614475B8 (pt) * 2005-08-03 2021-05-25 Fraunhofer Usa Inc polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
KR20080106433A (ko) * 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
CA2642056A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
WO2007137984A2 (en) 2006-05-25 2007-12-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
CN1865281B (zh) * 2006-06-02 2012-08-22 北京大学人民医院 卵巢癌抗独特型抗体6b11 t细胞表位肽及其应用
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
US8999634B2 (en) 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
CA2685558A1 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
CA2692933C (en) * 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
BRPI0813630A2 (pt) * 2007-07-27 2019-09-24 Facet Biotech Corp combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)
CN101820903A (zh) * 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
EP2192922A4 (de) 2007-09-17 2010-09-29 Univ California Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
EP2427479B1 (de) 2009-05-07 2018-11-21 The Regents of The University of California Antikörper und verfahren zu ihrer verwendung
WO2011027349A1 (en) * 2009-09-06 2011-03-10 Protab Ltd. Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
PL2563813T3 (pl) 2010-04-30 2016-01-29 Alexion Pharma Inc Przeciwciała anty-C5a i sposoby stosowania przeciwciał
WO2012027440A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
EP2621950A4 (de) 2010-09-27 2015-09-02 Janssen Biotech Inc Antikörper zur bindung von humanem kollagen ii
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
WO2013009767A2 (en) 2011-07-12 2013-01-17 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
EP2916835A4 (de) 2012-11-12 2016-07-27 Redwood Bioscience Inc Verbindungen und verfahren zur herstellung eines konjugats
JP2016505528A (ja) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質の化学修飾のためのピクテ−スペングラーライゲーション
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3470081A1 (de) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
EP3171896A4 (de) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
EP3209769B1 (de) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur induzierung der phagozytose von mhc-klasse-i-positiven zellen und verhinderung von anti-cd47/sirpa-resistenz
WO2016081455A1 (en) 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP6961625B2 (ja) 2016-06-09 2021-11-10 ペリカン セラピューティクス，インコーポレイテッド 抗ｔｎｆｒｓｆ２５抗体
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
EP3655031A1 (de) 2017-07-21 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Immunogene zusammensetzungen gegen neisseria meningitidis
US20200283537A1 (en) 2017-11-14 2020-09-10 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
WO2023049867A1 (en) * 2021-09-24 2023-03-30 Seeker Biologics, Inc. Orai1 multispecific antibodies and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody

Also Published As

Publication number Publication date
WO1993011237A1 (en) 1993-06-10
GB9125979D0 (en) 1992-02-05
EP0667902A1 (de) 1995-08-23
DE69232968D1 (de) 2003-04-24
EP0667902B1 (de) 2003-03-19
ATE234923T1 (de) 2003-04-15
DK0667902T3 (da) 2003-04-22
JP3339637B2 (ja) 2002-10-28
US5502167A (en) 1996-03-26
ES2194011T3 (es) 2003-11-16
JPH07504808A (ja) 1995-06-01

Similar Documents

Publication Publication Date Title
DE69232968T2 (de) CDR ausgetauschte humanisierte chimäre T-Zellenantikörper.
SG165161A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
SG52215A1 (en) Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4
EP0724456A4 (de) Antikörper gegen cd40
IL108501A0 (en) Novel antibodies and pharmaceutical compositions containing them
ZA954990B (en) Interleukin-5 specific recombinant antibodies
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
EP0499176A3 (en) Monoclonal antibodies against human pancreatic islet cells
Dalesandro et al. Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibody
DE3775182D1 (de) Monoklonale antikoerper gegen menschliche ige-rezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee